Neil Cashman Acquires 15,000 Shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN) Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) insider Neil Cashman acquired 15,000 shares of ProMIS Neurosciences stock in a transaction that occurred on Monday, February 10th. The shares were purchased at an average price of $0.97 per share, with a total value of $14,550.00. Following the transaction, the insider now owns 16,617 shares of the company’s stock, valued at $16,118.49. The trade was a 927.64 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ProMIS Neurosciences Price Performance

Shares of NASDAQ:PMN traded up $0.01 during trading on Wednesday, hitting $0.91. The company’s stock had a trading volume of 47,892 shares, compared to its average volume of 46,318. The company has a 50-day moving average of $0.94 and a 200-day moving average of $1.08. The firm has a market cap of $29.85 million, a price-to-earnings ratio of -9.13 and a beta of 0.56. ProMIS Neurosciences, Inc. has a 12 month low of $0.87 and a 12 month high of $2.61.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Great Point Partners LLC purchased a new position in ProMIS Neurosciences during the third quarter valued at approximately $3,488,000. Ally Bridge Group NY LLC increased its stake in ProMIS Neurosciences by 50.3% in the 3rd quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock worth $1,991,000 after buying an additional 533,023 shares in the last quarter. Finally, Sphera Funds Management LTD. boosted its stake in shares of ProMIS Neurosciences by 6.3% in the third quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock worth $2,412,000 after acquiring an additional 115,084 shares during the period. 50.13% of the stock is currently owned by institutional investors.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.